Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in […]

Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on

Stallion Uranium Announces Mobilization for Winter Drilling Program, Appoints Paulo Santos as Chief Financial Officer GlobeNewswire January 05, 2026 VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion“) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce the mobilization of personnel and equipment for the upcoming diamond

Transocean Ltd. Announces Contract Award and Extension Totaling $168 Million GlobeNewswire January 05, 2026 STEINHAUSEN, Switzerland, Jan. 05, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced a contract award and an extension, respectively, for two of its drilling rigs. Together, the fixtures represent approximately $168 million of firm backlog. In Brazil, the

(NasdaqGM:NRXP), Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo(R) Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment protocols and clinical training with neurocare expertise in neuromodulation technology and NRx Pharmaceuticals neuroplastic drug development program. Pilot program with a state first-responder agency

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions GlobeNewswire January 05, 2026 Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo(R) Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment

(CBOE:MSST),(CBOE:NVIT),(CBOE:TEST), CHICAGO and MILWAUKEE and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — YieldMax(R) today announced distributions for the YieldMax(R) Performance & Distribution Target 25(TM) ETFs listed in the table below. The Fund seeks to generate income with a 25% target annual income level. Group 3 Distribution Announcement: Ex. & Record Date: January 6, 2026

YieldMax(R) ETFs Announces Distributions on MSST, NVIT, and TEST GlobeNewswire January 05, 2026 CHICAGO and MILWAUKEE and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — YieldMax(R) today announced distributions for the YieldMax(R) Performance & Distribution Target 25(TM) ETFs listed in the table below. The Fund seeks to generate income with a 25% target annual income

DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM), an Ethereum-based DeFi crypto project, says its token sale has reached Phase 7 while development continues on its core lending and borrowing protocol. The team describes Phase 7 as another step in a staged sale process that has moved the token price